Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
IRD on Nasdaq
Shares outstanding
68,652,138
Price per share
$2.01
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
19,036,274
Total reported value
$31,912,032
% of total 13F portfolios
0%
Share change
+1,523,078
Value change
+$2,765,657
Number of holders
47
Price from insider filings
$2.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 10% 0% $7,500,359 +$1,863,172 6,250,299 +33% Nantahala Capital Management, LLC 30 Jun 2025
Foundation Fighting Blindness Retinal Degeneration Fund 8% -49% $10,599,890 -$7,720,000 5,492,171 -42% Foundation Fighting Blindness Retinal Degeneration Fund 09 Dec 2025
PERCEPTIVE ADVISORS LLC 10% $4,014,346 4,510,501 Perceptive Advisors LLC 24 Mar 2025

As of 30 Sep 2025, 47 institutional investors reported holding 19,036,274 shares of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD). This represents 28% of the company’s total 68,652,138 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
PERCEPTIVE ADVISORS LLC 6.3% 4,325,000 0% 0.21% $7,136,250
BIOS Capital Management, LP 5.4% 3,683,429 0% 7.4% $6,593,338
Nantahala Capital Management, LLC 4.9% 3,345,923 0% 0.34% $5,520,773
VANGUARD GROUP INC 2% 1,342,025 +35% 0% $2,214,341
Mink Brook Asset Management LLC 1.8% 1,237,947 +3.4% 1.4% $2,042,613
Opaleye Management Inc. 1.6% 1,100,000 -9.8% 0.26% $1,815,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.4% 954,996 0% $1,575,743
Bleichroeder LP 1.1% 736,842 0% 0.24% $1,215,789
Voss Capital, LP 0.82% 562,377 +3.9% 0.05% $927,922
GEODE CAPITAL MANAGEMENT, LLC 0.68% 468,937 +32% 0% $773,844
RENAISSANCE TECHNOLOGIES LLC 0.25% 173,809 +13% 0% $286,785
STATE STREET CORP 0.21% 145,873 +107% 0% $240,690
Creative Planning 0.19% 128,366 0% $211,804
CITADEL ADVISORS LLC 0.17% 113,416 0% $187,136
TWO SIGMA INVESTMENTS, LP 0.16% 108,338 +170% 0% $178,758
NORTHERN TRUST CORP 0.1% 68,228 0% 0% $112,576
XTX Topco Ltd 0.08% 51,757 +227% 0% $85,399
BlackRock, Inc. 0.07% 46,094 0% 0% $76,055
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.06% 42,065 0% 0% $69,407
Empowered Funds, LLC 0.06% 42,065 0% 0% $69,407
SIMPLEX TRADING, LLC 0.05% 32,847 0% $54,000
CAPTRUST FINANCIAL ADVISORS 0.05% 32,000 0% 0% $52,800
MORGAN STANLEY 0.04% 28,606 0% 0% $47,200
BLAIR WILLIAM & CO/IL 0.04% 24,466 0% 0% $40,369
RAYMOND JAMES FINANCIAL INC 0.03% 22,508 +96% 0% $37,138

Institutional Holders of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 11,836 $23,790 +$23,790 $2.01 1
2025 Q3 19,036,274 $31,912,032 +$2,765,657 $1.65 47
2025 Q2 17,503,196 $16,482,508 +$2,741,386 $0.94 43
2025 Q1 14,560,311 $14,686,745 +$11,049,642 $0.98 46
2024 Q4 3,678,848 $4,378,448 +$106,957 $1.19 42
2024 Q3 2,531,596 $3,315,513 -$283,780 $1.31 37
2024 Q2 2,696,097 $4,126,103 -$1,250,858 $1.53 37
2024 Q1 3,374,307 $6,780,798 -$879,463 $2.01 48
2023 Q4 3,696,741 $11,127,334 -$257,873 $3.01 47
2023 Q3 3,768,545 $12,624,748 -$57,059 $3.35 51
2023 Q2 3,675,838 $15,952,413 +$1,001,478 $4.34 53
2023 Q1 3,457,077 $12,962,551 +$1,457,390 $3.75 40
2022 Q4 3,099,588 $10,946,085 +$1,241,958 $3.53 34
2022 Q3 2,825,667 $5,686,000 +$828,898 $2.01 34
2022 Q2 2,406,842 $4,622,000 +$368,935 $1.92 34
2022 Q1 2,052,047 $6,623,000 -$413,208 $3.23 34
2021 Q4 2,169,473 $8,073,000 +$1,421,026 $3.73 32
2021 Q3 1,679,507 $8,621,000 +$3,116,773 $5.15 26
2021 Q2 1,068,443 $5,606,000 +$363,613 $5.27 29
2021 Q1 912,180 $5,265,087 -$7,635,044 $5.81 21
2020 Q4 2,179,512 $14,147,013 +$722,017 $6.51 8